Inbiomotion, an Ysios Capital portfolio company, both members of CataloniaBio & HealthTech, and Source BioScience, have signed an exclusive agreement to start offering the MAF Test® as a service in United Kingdom and Ireland. The MAF Test® predicts the prognosis of breast cancer patients and helps oncologists to identify those patients who may be able to prevent recurrence and benefit from adjuvant treatment with bisphosphonates, which are commonly used to treat osteoporosis. The test also identifies those patients whose prognosis would worsen if treated with bisphosphonates.
Thanks to this agreement, the MAF Test® could increase the survival of 8 out of 10 of the 56,000 early-stage breast cancer patients diagnosed each year. Breast cancer is the most common form of cancer among women, with more than globally 2 million new cases diagnosed each year. Approximately 1 in 8 women will develop breast cancer in their lifetime and, of these, 15-20% will eventually develop metastases. Having the capacity to identify those patients with a higher risk of recurrence and being able to personalise their treatment is vital for their survival and quality of life.
Ralf van den Berg, Chief Operating Officer of Inbiomotion commented, "We are thrilled to announce a groundbreaking partnership between Inbiomotion and Source BioScience, bringing the cuttingedge MAF Test® to the forefront of precision medicine in the United Kingdom and Ireland. This collaboration marks an important milestone in advancing diagnostic capabilities, empowering healthcare professionals with a powerful tool to enhance patient care for early breast cancer patients. Together, Inbiomotion and Source BioScience are committed to delivering innovative solutions that revolutionize the landscape of personalised medicine, ultimately improving outcomes and quality of life for individuals facing complex medical challenges."
Comments